We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Apoptosis Assay Predicts Differences in Late Toxicity

By HospiMedica staff writers
Posted on 05 Aug 2003
The use of an apoptosis assay can help predict the differences in late toxicity among individuals with solid tumors and thus may be used as a rapid screen for genetically hypersensitive patients. More...
This finding was presented at annual meeting of the American Association for Cancer Research in Washington, DC (USA).

Researchers tested 339 patients, treated by curative radiation therapy, using a rapid apoptosis assay where fresh blood samples were irradiated with 8-Gy x-rays. Median CD4 and CD8 T-lymphocyte apoptosis was 12% and 20%, respectively. While no correlation was found between early toxicity and T-lymphocyte apoptosis, the rapid assay significantly predicted the clinically critical grade 2 and 3 late toxicities. The majority of the patients in the study had breast (149), head and neck (75), or prostate cancers (36). The median follow-up for all treated patients was 29 months.

"We believe that this is the first rapid assay of intrinsic radiosensitivity that has been confirmed prospectively and can be used to prospectively eliminate from trials all patients likely to display severe late effects, which has been a recurring concern in the clinic when developing new protocols,” said Nigel Cromptom, Ph.D., professor of biology at Cornerstone University (Grand Rapids, MI, USA) and one of the investigators.




Related Links:
Cornerstone Univ.

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.